Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Supernus ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 3.2% in the afternoon session after ...

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They ...

Review the current Supernus Pharmaceuticals Inc (SUPN:XNAS) dividend yield and history to decide if SUPN is the best investment for you.

Two weeks after Supernus unveiled the Sage Therapeutics acquisition, all 338 employees from the struggling biotech are being laid off.

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by late August.

Supernus Pharmaceuticals’ first quarter results were met with a negative market reaction, despite revenue and non-GAAP profit exceeding Wall Street’s expectations. Management attributed the ...

Review which funds and institutions currently hold Supernus Pharmaceuticals Inc (SUPN:XNAS) stock for ownership information.